Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Zealand Pharma A/S is seeking a Senior Principal Scientist to anchor small molecule medicinal chemistry efforts across our obesity and metabolic health programs. You will lead design, optimization, and profiling of drug candidates while collaborating with medicinal chemistry, computational chemistry, pharmacology, and ADME teams.
You will also manage external CROs, guide project strategies, and contribute to cross-functional development plans to bring candidates toward preclinical and clinical
Do you know what it takes to advance a small molecule preclinical asset into clinical development, and do you also have a keen interest in expanding your horizon into peptide drug discovery? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As a Senior Principal Scientist or Principal Scientist, you will join our Discovery Research team at the most exciting time for the company, acting as the company anchor in external collaborations with partners on small molecule assets. You will take an active role in global, cross-organizational project teams, providing input to compound design and securing fast progress of suitable lead candidates within obesity, rare diseases, and chronic inflammation. Working closely with colleagues across medicinal chemistry, computational chemistry, in vitro/in vivo pharmacology, and ADME, you will bring a broad drug discovery understanding and mindset to everything you do.
You will join the Medicinal & Computational Chemistry team, a mix of scientists at varying levels of experience and laboratory technicians, working together to drive structure-based and computational approaches across our drug discovery pipeline.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.
Learn more at www.zealandpharma.com.